STAT August 7, 2024
Purdue Pharma, the company best known for fueling the opioid crisis by misleadingly marketing the infamous painkiller OxyContin, received approval on Wednesday for a new auto-injector device used to reverse opioid overdoses.
The announcement represents the latest in a string of recent approvals for products that use nalmefene, essentially a more powerful version of its better-known chemical cousin, naloxone.
The Food and Drug Administration’s approval of Zurnai, as the device is known, also underscores Purdue’s continued effort to play a role in the nationwide response to the opioid crisis.
“The FDA remains focused on broadening access to opioid overdose reversal agents, including naloxone and nalmefene,” Robert Califf, the agency’s commissioner, said in a statement. “Today’s approval adds...
Today's Sponsors
Today's Sponsor